Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-D-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC)

doi:10.1016/j.bmc.2009.11.033

Bioorg Med Chem. Author manuscript; available in PMC 2011 January 15.

Published in final edited form as:

Bioorg Med Chem. 2010 January 15; 18(2): 896.

Published online 2009 November 20. doi: 10.1016/j.bmc.2009.11.033

PMCID: PMC2818544

NIHMSID: NIHMS161253

Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-D-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC)

Sharmila Sivendran,^a^† Victoria Jones,^b^† Dianqing Sun,^c^‡ Yi Wang,^d Anna E. Grzegorzewicz,^b Michael S. Scherman,^b Andrew D. Napper,^a^§ J. Andrew McCammon,^d Richard E. Lee,^c^¶ Scott L. Diamond,^a and Michael McNeil^b^*

^a Penn Center for Molecular Discovery, Department of Chemical and Biomolecular Engineering Institute for Medicine and Engineering, 1024 Vagelos Research Laboratories, University of Pennsylvania, Philadelphia, PA 19104 U.S.A.

^b Colorado State University, Department of Microbiology, Immunology and Pathology, 1682 Campus Delivery Ft. Collins, CO 80523-1682 U.S.A

^c Dept. of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN U.S.A.

^d Howard Hughes Medical Institute, University of California at San Diego, 9500 Gilman Dr La Jolla, CA 92093 U.S.A

^* Corresponding Author. Ph: (970) 491 1784; Fax: (970) 491 1815, Email: mmcneil/at/colostate.edu

^†Equal Contributors.

^‡Present Address: Department of Pharmaceutical Sciences, College of Pharmacy, University of Hawaii at Hilo, 34 Rainbow Drive, Hilo, HI U.S.A.

^§Present Address: High-Throughput Screening & Drug Discovery Lab Nemours Center for Childhood Cancer Research, 1701 Rockland Road, Wilmington, DE 19803 U.S.A.

^¶Present address: Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, MS#1000, Memphis, TN 38105 U.S.A.

The publisher's final edited version of this article is available at Bioorg Med Chem

See other articles in PMC that cite the published article.

Publisher's Disclaimer

Abstract

High-throughput screening of 201,368 compounds revealed that 1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one (SID 7975595) inhibited RmlC a TB cell wall biosynthetic enzyme. SID 7975595 acts as a competitive inhibitor of the enzyme’s substrate and inhibits RmlC as a fast-on rate, fully reversible inhibitor. An analog of SID 7975595 had a K_i of 62 nM. Computer modeling showed that the binding of the tethered two-ringed system into the active site occurred at the thymidine binding region for one ring system and the sugar region for the other ring system.

Keywords: RmlC inhibitor, tuberculosis, TB cell wall, TB drug discovery

1. Introduction

Tuberculosis (TB) is a contagious disease and one of the leading causes of death world-wide. According to the World Health Organization (WHO), more than two billion people, one third the world’s total population, are infected with the TB bacterium, including 10–15 million in the United States alone. The emergence of drug-resistant strains has been a huge problem in recent years ¹, and now strains resistant to both first and second line antibiotics have clearly been identified ²^,³. Although the incidence of tuberculosis has increased over the past decade, no tuberculosis-specific drugs have been discovered over the last 40 years.

Two of the first line TB drugs, isoniazid and ethambutol, attack the biosynthesis of the unique TB cell wall. Resistance against these drugs ¹ makes the development of new drugs directed against the TB cell wall critical. A highly desirable cell wall target is the linker disaccharide that is instrumental in tethering the peptidoglycan layer to the mycolic acid inner leaflet of the outer membrane ⁴ as illustrated in Fig. 1. Specifically, the formation of the rhamnosyl residue (Fig. 1) was targeted using a high-throughput screen for compounds that inhibit the conversion of TDP-6-deoxy-D-xylo-hexopyranosid-4-ulose (TDP-KDX) to TDP-L-rhamnose (TDP-Rha), catalyzed by two enzymes, TDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase (RmlC) and TDP-deoxy-L-lyxo-4-hexulose reductase (RmlD) (Figs 1 & 2). As expected these enzymes have been shown to be essential ⁵^,⁶, and crystal structures for RmlC from M. tuberculosis with and without the substrate analog TDP-Rha ⁷ and RmlD from Salmonella enterica ⁸ have been published. An assay to search for inhibitors of them has been described ⁹ and was revamped for the studies herein.

Figure 1

M. tuberculosis cell wall structure and its biosynthesis

Figure 2

The assay for RmlC and/or RmlD inhibitors

As part of the National Institutes of Health Molecular Libraries Screening Centers Network (MLSCN), Penn Center for Molecular Discovery (PCMD) performs high-throughput screens against various targets and deposits data into PubChem. Herein we report the high-throughput screen (HTS) of 201,368 compounds from the NIH Molecular Libraries Small Molecule Repository (BioFocus DPI) against Mycobacterium tuberculosis RmlC and RmlD in the same assay. The results of this screen are available on PubChem as BioAssay IDs (AIDs) 1532, 1533, 1695 and 1696.

The most potent hit from the screen was further studied to determine which enzyme, RmlC or RmlD, was the target of inhibition, and its activity was confirmed by re-synthesis of the compound. Kinetic studies to identify its mode of inhibition were undertaken and structural analogs of the hit compound were also tested to initiate structure-activity relationships (SAR). Finally, preliminary studies of the action of this class of compounds against whole M. tuberculosis bacteria were performed.

2. Results

2.1 Characterization of M. Tuberculosis RmlB, RmlC, and RmlD Enzymes

Rhamnosyl biosynthetic enzymes, RmlB, RmlC and RmlD, were cloned and expressed in E. coli and purified to homogeneity. The purity of the enzymes was seen by single bands on polyacrylamide gel electrophoresis with SDS. The RmlC and RmlD enzymes exhibit single bands of molecular weights of approximately 25,000 and 40,000, respectively (data not shown).

2.2 Optimization of Assay

The assay measures the activity of the two enzymes RmlC and RmlD that act sequentially in the formation of TDP-rhamnose (TDP-Rha). The RmlC enzyme converts TDP-6-deoxy-D-xylo-hexopyranosid-4-ulose (TDP-KDX) to TDP-6-deoxy-L-lyxo-hexopyranosid-4-ulose (TDP-KDL) and RmlD converts TDP-KDL to TDP-Rha with the use of NADPH (Fig. 2). TDP-KDX was synthesized enzymatically by converting TDP-glucose to TDP-KDX using RmlB, allowing the reaction to go to completion (the reaction is irreversible), and TDP-KDX was used directly without purification. The final assay consisted of RmlC, RmlD, and NADPH, and was initiated by the addition of TDP-KDX. The activity of the enzymes was detected by the time-dependent decrease in fluorescence observed upon the oxidation of NADPH to NADP. The K_m values of TDP-KDX and NADPH were determined to be 211and 12 μM, respectively (Fig. 3A and 3B). The assay was optimized by varying the concentrations of RmlC, RmlD, NADPH, and TDP-KDX to obtain a linear decrease in fluorescence over 90 min (data not shown) and to keep the substrate concentrations as near to their K_m values as possible (200 μM TDP-KDX and 25 μM NADPH were selected for the screen). The amounts of RmlC and RmlD were balanced such that if the amount of either enzyme was decreased the rate of the overall reaction decreased (i.e. neither enzyme was in excess). This ensured that the assay was sensitive to inhibition of either enzyme. The IC₅₀ of the known inhibitor, TDP, was determined to be 340 μM (Fig. 3C) The QC plate gave a Z′-value of 0.78 with TDP (Fig. 3D).

Figure 3

Assay optimization

2.3 High-Throughput Screening

HTS of the 201,368 compounds of the MLSCN library is summarized in Table 1. The screen was performed with mixtures of four compounds per well in 384-well plates. When a given well showed greater than 30% inhibition the 4 individual compounds were retested in individual wells. The average Z′-factor for the screen was 0.67 ± 0.05, indicating good plate uniformity throughout the screen (Fig. 3E) ¹⁰. A total of 2328 wells showed greater than 30% inhibition and from these wells 5,266 individual compounds were obtained and tested as a single compound. Of these, 470 showed inhibition of greater than 30% and from these 388 were tested for dose response.

Table 1

High-throughput screen of 201,368 compounds of the MLSCN library

2.4 IC₅₀ Determination of Hits

Compounds that gave greater than 30% inhibition in single well assays were tested in dose-response. Of the 388 compounds tested, 372 gave IC₅₀ values of less than 55 μM and were selected as active compounds (Table 1). When tested in buffer alone in the IC₅₀ format (i.e. without enzyme or substrates), most of the active compounds gave the same dose-response curves independent of the RmlC and RmlD enzymes, indicating that they are fluorescent at the excitation/emission wavelengths of 340/460 nm and that for an unknown reason this fluorescence increased with time leading to a false positive result. (Often these false positive compounds gave percent inhibition much greater than the theoretical maximum value.) All compounds with IC₅₀ values less than 20 μM were tested in buffer alone and 14 non-fluorescent compounds were selected as true hits. The IC₅₀ values of the 14 compounds ranged from 0.398 to 18.13 μM. 1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one, SID 7975595, with an IC₅₀ of 0.398 μM (Fig. 4A) was the best hit and was further studied.

Figure 4

Characterization of SID 7975595

2.5 Determination of which enzyme, RmlC or RmlD), is being inhibited

The enzyme being inhibited by compound SID 7975595 was determined by varying the RmlC enzyme concentration while keeping the RmlD concentration constant and vice versa (Fig. 4B). The data show that the IC₅₀ remains constant when the RmlD concentration is increased up to 80-fold, but the IC₅₀ changes as the RmlC concentration is changed, demonstrating that the enzyme being inhibited by compound SID 7975595 is RmlC. These results were confirmed using a GC/MS based assay ¹¹ in which the amount of product of RmlC, TDP-6-deoxy-L-lyxo-hexopyranosid-4-ulose is determined directly after 4-keto reduction and further derivatization. The percent inhibition of RmlC was calculated as 52, 72, and 83% at 0.25, 0.5, and 5 μM SID 7975595, respectively. Although this method is inherently less accurate (extremely low amounts of product must be quantitated because of the 2% conversion equilibrium value of product versus substrate ¹¹) it clearly confirmed in a direct assay the action of SID 7975595 against RmlC.

2.6 Kinetic Characterization of Inhibition

The K_m(obs) of TDP-KDX was determined in the presence and absence of compound SID 7975595 to determine if it was acting as a competitive or non-competitive inhibitor (Table 2). The data show it is a classical competitive inhibitor, where at increasing concentrations of the compound (0.1, 0.15, and 0.2 μM) the K_m(obs) increases from 200 μM in the absence of compound to almost 700 μM in the presence of 0.2 μM compound, while the V_max value changes only slightly compared with the value measured in the absence of compound (the slight increase may be an artifact of the inability to use a high enough concentration of TDP-KDX in the presence of inhibitor). A plot of K_m(obs) versus [I], was used to determine the K_i of SID 7975595, which is equal to K_m/slope (Fig. 4C). The K_i value for SID 7975595 was found to be 0.1 μM.

Table 2

TDP-KDX K_m(obs) and V_max for the RmlC reaction at various concentrations of SID 7975595

To check for the rate of onset of inhibition of RmlC by SID 7975595, its IC₅₀ was determined after various times of pre-incubation with RmlC before assaying for enzyme activity (Fig. 5A and 5B). If the onset of inhibition due to SID 7975595 is slow, the IC₅₀ would be expected to decrease as the pre-incubation time is increased. No such decrease in IC₅₀ was observed; the reason for the slight increase with pre-incubation is not clear. To determine whether or not the binding was reversible, SID 7975595 at 10 times its IC₅₀ was pre-incubated with RmlC at 100 times its final assay concentration, before diluting the compound-RmlC mixture 100-fold and monitoring the enzyme activity over time. During the pre-incubation the concentration of inhibitor is much higher than the enzyme (20 μM versus 0.0012 μM); thus if inhibitor binding is irreversible essentially all of the enzyme will be inactivated and remain inhibited upon dilution. However, the results shown in Fig. 5C and 5D indicate that the compound is a fully reversible inhibitor; the slopes (taken from 80 to 200 min) observed in the assay after pre-incubation of compound and enzyme for 0.5 hr or 0 hr are very similar to that of the control with no SID 7975595 in the assay. For an additional control, SID 7975595 was included in the dilution buffer at 3.98 μM, and inhibition of the reaction occurred as expected (Fig. 5C and 5D). (The reason for the initial period of 40–50 minutes before the decrease in fluorescence begins is not understood; however the phenomenon occurs in this dilution experiment whether or not inhibitor is present and a similar increase of fluorescence early in the reaction also occurs in the absence of RmlC substrate, TDP-KDX.)

Figure 5

Characterization of Inhibition

2.7 Preliminary Structure-Activity Relationships

Analogs of SID 7975595 (77070, 77071, 77072, 77073, and 77074 in Table 3) were purchased from ChemBridge. In addition, to confirm their activity, SID 7975595 and 77074 were resynthesized (see materials and methods). The activity of the resynthesized compounds was indistinguishable from the ChemBridge compounds. Additional analogs, 78531, 78532, and 78533 (Table 3) were synthesized, and the IC₅₀ values of all these triazinoindol-benzimidazolones are reported in Table 3. The IC₅₀ values of 77070 shows that when the R₁ ethyl group attached to the indol nitrogen is replaced by a benzyl group (77070) the IC₅₀ increase to 3 μM or approximately 15 fold. However, when R₁ is H (77073) the IC₅₀ also increases about the same amount. The IC₅₀ is also affected by subtle changes to the R₁ group; most dramatically the saturation of an allyl group (77074) to an n-propyl group (77071) caused a 10 fold increase in the IC₅₀. Altogether these data suggested that the R₁ portion of the compound must be involved in the binding of the compound in the active site (see modeling studies below). Consistently, the allyl substituent (77074) is the best inhibitor, and use of the Cheng-Prusoff equation ¹², K_i=IC₅₀/(1+[S]/K_m), to convert the IC₅₀ to K_i (an approach using less experimental data than that of Fig. 4C) yields a K_i of 62 nM. Oxidation of the thioether to sulfone did not substantially alter the enzyme inhibition (Table 3), however, the resulting compounds did show some chemical instability when stored for longer periods of time, disfavoring their further follow up. Interestingly, the introduction of methyl group in the R₂ position in 78531 (Table 3) substantially reduced the ability of the triazinoindol-benzimidazolone to inhibit RmlC. Finally, variation of the spacer region between the two rings from 4 atoms (77074) to 2 atoms (SID 7972845) dramatically reduced the activity of the inhibitor. With this SAR in hand, we modeled the compounds in the active site of the known structure of RmlC ⁷.

Table 3

IC₅₀ values for inhibition of RmlC by substituted triazinoindol-benzimidazolones, and the MIC values of these compounds against M. tuberculosis in culture.

2.8 Modeling of triazinoindol-benzimidazolones into the active site of RmlC

Prior to the docking of triazino-indols, the substrate analog, TDP-Rha, was re-docked into RmlC using both Glide and Autodock Vina. The docking poses generated by both programs were very similar to the crystal structure, a root mean square deviation (RMSD) of 0.9 Å (Glide SP), 1.7 Å (Glide XP), and 2.0 Å (Autodock Vina), respectively. As the RmlC-TDP-Rha complex was not part of either program’s training set ¹³, the relatively small RMSD values suggest that both programs performed well in the re-docking of TDP-Rha (see Fig. 6A).

Figure 6

Model of SID 7975595 docked in the active site

The docking of SID 7975595 and its structural analogs yielded two different poses using Glide and Autodock Vina (Fig. 6B and 6C). In both poses, one ring system interacts with the thymidine binding regions of the active site and the other ring system with the sugar binding ring of the site (Figs. 6A, 6B, and 6C); the difference of the two poses being which ring system is in which position. In the Glide pose, the tricylic ring of SID 7975595 forms a stacking interaction with Tyr138 (thymidine binding region), whereas in the Autodock Vina pose, this ring is deeply inserted into the active site near Lys72 (sugar binding region). Although we cannot completely rule out either of the two poses without a crystal structure of RmlC-SID 7975595 complex, the Autodock Vina pose appears to be more consistent with the experimental data. As mentioned above, an extra methyl group on 78531 dramatically reduced its inhibitory activity and increased its IC₅₀ from 0.12 μM of the parent compound 77074 to 20 μM. In the Autodock Vina pose, the tricyclic ring is inserted into the active site, where an extra methyl group at the R₂ position will cause steric clash with His119 and Phe121 (Fig. 6D). Therefore, the Autodock Vina pose (Fig. 6B) better explains the reduced activity of 78531, and will be our focus in the following discussions.

As shown in Fig. 6B, SID 7975595 forms a large hydrophobic contact with the protein, preventing water molecules from accessing residues Phe26 and Tyr132, as well as residues at the bottom of the active site, i.e., Val74, Phe121, and Val130. These hydrophobic interactions appear to be the main contribution to the affinity of the compound, although hydrogen bond interaction is also observed between a nitrogen atom on the tricyclic ring and residue Arg59 which are 2.3A apart. The R₁ substitutions on the tricyclic ring may help the compounds to secure a tight hydrophobic seal with the protein. As shown in Fig. 6B and and7A,7A, the ethyl and allyl groups form abundant hydrophobic contact with the protein near Tyr132, whereas a methyl or hydrogen R₁ group is unable to achieve such an effect. Interestingly, the large benzyl group of 77070 can be accommodated by a pocket near Glu143 and His62 (Fig. 7B). However, this conformation puts the benzyl ring near Lys72 and completely displaces water molecules hydrating this charged residue. This unfavorable desolvation effect may explain the reduced activity of the compound. Both Glide and Autodock Vina produced similar poses for SID 7972845, which is two carbons shorter than the highly active 77074 in the linker region connecting the two ring systems. The docking poses suggest that the shortened linker forces the compound to reorient in order to maintain hydrophobic contacts with the protein at both the bicyclic and tricyclic rings (Fig. 7C).

Figure 7

Docking poses of SID 7975595 structural analogs

2.9. MIC of Compound in M. tuberculosis Cells

Minimum inhibitory concentrations of the hit compound (SID 7975595) and some of its analogs against M. tuberculosis are shown in Table 3. Clearly the compounds are active, and there is a rough correlation between the activity against whole M. tuberculosis cells and the activity against RmlC. However, future studies, such as the determination of the MIC values in strains overexpressing RmlC and the search for the build up of intermediates such as TDP-Glc in cells treated with the RmlC inhibitors are required before the action of these compounds at the whole bacterial cell level can be concluded to be due to inhibition of RmlC.

2.9 Cytotoxicity of SID 7975595 in HAE Cells

Toxicity of compound SID 7975595 in mammalian cells was determined in human aortic endothelial cells (Fig. 4D). The data show that SID 7975595 has an IC₅₀ of approximately 75 μM in HAE cells while the positive control, doxorubicin, has an IC₅₀ of ~10 μM. The percent of DMSO introduced into the assay during the addition of SID 7975595 or doxorubicin has no effect on the cells, as shown in Fig. 4D.

3. Discussion

A screen of 201,368 compounds from the NIH Molecular Libraries Small Molecule Repository for molecules that have the potential to be developed into new drugs against tuberculosis has identified a new series of compounds that inhibit the activity of one of the essential cell wall biosynthetic enzymes of M. tuberculosis. The most potent hit from the screen, 1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one (SID 7975595), has a “two-headed” structure (triazinoindol as the larger head group and benzimidazolone as the smaller head group) so based on this parent structure we have called this series of compounds triazinoindol-benzimidazolones.

SID 7975595 acts as a classical competitive inhibitor of the RmlC enzyme by increasing the K_m for TDP-KDX without affecting the V_max and has a K_i of 100 nM. Comparison of the K_m of TDP-KDX and the K_i of the inhibitor suggests that the inhibitor bindings with an approximately 2000-fold higher affinity. SID 7972845 (Table 3) is identical to the most potent triazinoindol-benzimidazolone, 77074, except that the linker distance is two atoms in total between the two head groups in SID 7972845, versus four atoms in total in 70774. The IC₅₀ of SID 7972845 compared to77074 increases 86-fold to 10.3 μM, suggesting this linker distance between the two head groups has a significant effect on the occupancy of the active site by the inhibitor. This result is perhaps expected as the shorter linker drastically constrains the position of the two aromatic groups as shown in the docking experiments (Fig. 7C).

Interestingly, the docking result shows that one of the aromatic head groups occupies the thymidine binding region and the other group the sugar binding region in the active site. Indeed, the difference between the two docking poses from Glide and Autodock Vina revolves around which aromatic head group occupies which position and in reality this could be compound dependent. The docking results of the triazinoindol-benzimidazolones also suggest that hydrophobic interaction plays an important role in their binding to RmlC. The different substitutions at the R₁ position may affect the activity of the compounds by controlling the amount of hydrophobic contact with the protein. A small R₁ group (H atom) reduces the area of such contact, whereas a large R₁ group (benzyl ring) can cause an unfavorable interaction with charged and polar residues in the active site.

The ~10-fold increase in IC₅₀ when the R₁ allyl group is reduced from an allyl to an n-propyl group is at least partially explained by the loss of rotational entropy of the latter compound. Docking programs often assign a 0.65 kcal/mol penalty to the entropic loss of every rotatable bond, which corresponds to approximately a 3-fold difference in IC₅₀. However, the binding does exhibit a 10-fold difference and other factors may be involved as well.

Unfortunately, in both Glide and Autodock Vina results, the docking scores have a poor correlation with the measured IC₅₀ values (data not shown). Therefore, we could only establish a preliminary structure activity-relationship from the docking poses of SID 7975595 and its analogs. The poor correlation between docking scores and the IC₅₀, albeit disappointing, may be explained by a standard error of 2–3 kcal/mol often associated with docking scores ¹³^,¹⁴. In addition, the binding free energy differences of the SID 7975595 analogs, as estimated from their IC₅₀ values, are only 0.1 to 2.0 kcal/mol. Therefore, more accurate free energy calculations will be performed to obtain a better correlation with IC₅₀ and to guide compound design in our future work.

Analysis of the docking poses shows that the charged Lys72 is poorly hydrated upon binding of SID 7975595 and its analogs. As a consequence, it may be desirable to introduce a polar group on the tricyclic ring to provide a hydrogen bond partner for Lys72. Such a hydrogen bond enclosed in a hydrophobic environment has been found particularly favorable in many cases ¹⁴. Modeling and synthesis of these compounds are currently under way in our labs.

The triazinoindol-benzimidazolone SID 7975595 has been shown to be relatively non-toxic (Fig. 4D). The triazinoindol-benzimidazolones are also active against M. tuberculosis in culture (Table 3) although the activity is modest. Future studies will involve producing compounds with higher activities at the whole cell level by combining modeling and medicinal chemical efforts. With such compounds in hand efforts will focus on confirming that the target in whole bacteria is RmlC using genetic and precursor isolation approaches.

4. Experimental procedures

4.1 Materials

MOPS, Triton X-100 and TDP-Glucose were purchased from Sigma. MgCl₂ and glycerol were from Fisher. NADPH was purchased from Roche. Black 384-well low volume non-binding polystyrene plates were from Corning (Corning 3676). The 384-well v-bottom polypropylene plates (Greiner 781280), 1536-well v-bottom polypropylene plates (Greiner 782270), and 384-well white sterile tissue culture treated plates (Greiner 781080) were all from Greiner.

4.2 Protein Expression and Purification

The clone expressing Salmonella enterica RmlB used to make the TDP-KDX ¹⁵ was a gift from Jim Naismith, and RmlB was expressed and purified as described ¹⁵. (The RmlB from M. tuberculosis requires the addition of NAD for activity whereas NAD is tightly bound to the S. enterica RmlB as purified and no additional NAD is required. As we preferred not to introduce NAD into the system and were not testing for inhibition of RmlB, the S. enterica enzyme was used for substrate preparation). RmlC and RmlD from M. tuberculosis were cloned and expressed in Escherichia coli and purified as described ⁹.

4.3 Synthesis of TDP-KDX

The substrate, TDP-6-deoxy-D-xylo-hexopyranosid-4-ulose (TDP-KDX), for the RmlC enzyme was synthesized enzymatically by converting d-TDP-glucose (2.5 mg) to TDP-KDX using 2.4 μg of purified RmlB from Salmonella typhimurium ¹⁵ in 50 mM MOPS buffer, pH 7.4, at 30 °C for 1 hr. Aliquots of TDP-KDX were stored at −80 °C.

4.4 Assay Optimization

The activity of the M. tuberculosis cell wall enzymes, RmlC and RmlD, towards TDP-KDX was measured by the decrease in fluorescence observed upon the oxidation of NADPH to NADP, at excitation and emission wavelengths of 340 and 460 nm, respectively. The K_m for TDP-KDX (substrate) was determined by varying the TDP-KDX concentration from 0–1000 μM (10 point, 1.5-fold serial dilutions), while maintaining the NADPH concentration at 15 μM in a total volume of 10 μl. The NADPH (cofactor) K_m was determined by varying NADPH concentration from 0–100 μM (12 point, 1.5-fold serial dilutions), while maintaining TDP-KDX concentration at 200 μM in a total volume of 10 μl. The data were fit using the computer program XLfit using the “General pharmacology model 250” (Michaelis-Menten model).

Based on the K_m values of TDP-KDX and NADPH, assays were set up varying the TDP-KDX (100 and 200 μM) and NADPH (15 and 25 μM) concentrations as well as the concentrations of RmlC (8.75 × 10⁻⁵ to 5.25 × 10⁻⁴ μg/μl) and RmlD (2.175 × 10⁻⁴ to 1.31 × 10⁻³ μg/μl) in 50 mM MOPS, pH 7.4, containing 1 mM MgCl₂, 10% glycerol and 0.01% Triton X-100, at 25 °C (data not shown). The assay was monitored by the decrease in fluorescence over 3 hr on a plate reader (Perkin Elmer Envision 2102 Multilabel reader). Based on concentrations that gave a linear assay time course, final assay conditions for the HTS in 384-well plates (Corning 3676) were selected: 200 μM TDP-KDX, 25 μM NADPH, 2.63 × 10⁻⁴ μg/μl RmlC and 6.55 × 10⁻⁴ μg/μl RmlD in a volume of 10 μl, and monitoring of the decrease in 340/460 fluorescence over 90 minutes at 25° C. Under these conditions the amounts of RmlC and RmlD were balanced as determined by a significant decrease in rate when the amount of either enzyme was diminished.

TDP, a known inhibitor of the RmlC/RmlD enzymes, was used in a quality control (QC) plate to monitor the sensitivity of the enzymes towards inhibition throughout the course of the HTS. The IC₅₀ value of TDP was determined by dose response (16 point, 2-fold serial dilution, highest concentration of 30 mM) against 200 μM TDP-KDX, 15 μM NADPH, 1.8 × 10⁻⁴ μg/μl RmlC, and 4.4 × 10⁻⁴ μg/μl RmlD in a 384-well assay plate (Corning 3676). The change in fluorescence over 3 hr was monitored, and the IC₅₀ was calculated by a non-linear fit of the rate of change in fluorescence against TDP concentration. Based on the observed IC₅₀ of 340 μM, a solution of TDP in DMSO was added to a compound storage plate (Greiner 781280), set up to deliver a final assay concentration of 500 μM TDP, by pintool transfer of 0.12 μl (384-pin, V&P Scientific), expected to give slightly greater than 50% inhibition. The TDP storage plate contained 20 μl of 40.3 mM TDP in DMSO in columns 3–22, and 20 μl DMSO in columns 2 and 24 for controls (100% activity) and 20 μl DMSO in columns 1 and 23 for blanks (0% activity, no TDP-KDX). A TDP-containing QC plate was included in each HTS run and assayed using the same protocol as the test compound plates (see below).

4.5 High-Throughput Screening (HTS)

HTS of 201,368 compounds from the Molecular Libraries Screening Center Network (MLSCN) library was conducted in 384-well assay plates. The compounds were supplied as a smaller library (106,290 compounds) and as a larger library (214,178 compounds) that fully contained all of the 106,290 compounds of the first library but with no straightforward way to only screen the compounds not present in the smaller library. The entire smaller library was screened and 159,098 compounds from the larger library were screened of which 95,078 were not present in the smaller library leading to the screening of 201,368 unique compounds. The initial library was supplied by BioFocus DPI in 384-well storage plates and the expanded library supplied by BioFocus DPI in 1536-well compound storage plates. The 384-well library (supplied as 10 mM solutions in DMSO in v-bottom plates) was screened as mixtures of four compounds per well, by transfer of compounds from four 384-well compound storage plates into a single 384-well assay plate. Thus, 384-well dilution compound plates (Greiner 781280) were made at 0.5 mM in 20 μl DMSO (one compound per well) from the 10 mM plates supplied by BioFocus DPI. Mixtures were generated during HTS, using a pintool (384-pin, V & P Scientific) to transfer 0.12 μl of compound from the same well number (e.g. A3) from four different 384-well 0.5 mM dilution compound plates into a single well of a 384-well assay plate containing 4 μl of H₂O (again the same well number, e.g., A3). The final compound concentration was 5.5 μM per compound (22.0 μM total per well). A Multidrop reagent dispenser (Thermo) was used to dispense 5 μl of 83.5 mM MOPS buffer containing 2x RmlC, RmlD and NADPH, and a Multidrop Micro (Thermo) was used to dispense 1 μl of 83.5 mM MOPS buffer containing 10x TDP-KDX. Blank columns (1 and 23) contained 1 μl of 83.5 mM MOPS buffer instead of TDP-KDX. The final RmlC, RmlD, and NADPH concentrations in the 10.5 μl assay were 2.63 × 10⁻⁴ μg/μl, 6.53 × 10⁻⁴ μg/μl, and 25 μM, respectively, and the final concentration of TDP-KDX was 200 μM. The final buffer concentration was 50 mM MOPS buffer, pH 7.4 with 1 mM MgCl₂, 10% glycerol, and 0.01% Triton X-100. The assay was monitored by the change in NADPH fluorescence at 25 °C, measured at time 0 and after 90 minutes, at excitation and emission wavelengths of 340 and 460 nm, respectively. Data were analyzed in IDBS ActivityBase, and the percent inhibition of each compound was calculated from the change in fluorescence over 90 min (ΔSignal), calculated from t=0 and t=90 min reads, and the mean of the change in plate controls and blanks over 90 min, using the following equation:

The 159,098 compounds in the 1536-well library were supplied by BioFocus DPI as 2.5 mM solutions in DMSO, stored in 1536-well v-bottom compound plates. These compounds were also screened as mixtures of four compounds per well in 384-well assay plates. Mixtures were generated by pintool (384-pin) transfer of 0.091 μl of compound from each of the four quadrants of a 1536-well compound plate into a single well of a 384-well compound dilution plate (Greiner 781280) containing 25 μl of H₂O. For example, compounds in wells A5, A6, B5, and B6 of a 1536-well compound plate were mixed in well A3 of a 384-well compound dilution plate. Four μl from each well of the compound dilution plate were transferred into a 384-well assay plate (Corning 3676) using a 384-tip pipetting head (PerkinElmer Evolution P3 Pipetting Platform). The well location of the compounds was unchanged during the transfer into the assay plate; for example, the mixture of four compounds in well A3 of a compound dilution plate was transferred to well A3 of the corresponding assay plate. The 384-well mixture dilution compound plate contained 9.1 μM of each compound and a total of 36.8 μM in 25 μl H₂O, and the final assay plate contained 3.64 μM of each compound and a total mixture concentration of 14.6 μM in 10 μL in each well. The additions of RmlC, RmlD, and NADPH (5 μl) and TDP-KDX (1 μl), and the HTS assay were the same as in the HTS of the 384-well compound plates. The data were analyzed in IDBS ActivityBase, as described above.

The compounds that gave greater than 30 % inhibition in the HTS of the 384- and 1536-well compound plates were selected as hits and retested as single compounds. Compounds were ordered from BioFocus DPI, diluted into 384-well compound plates (0.5 mM), transferred by pintool into 4 μl of H₂O in assay plates to give a final concentration of 5.5 μM in a final assay volume of 10 μl, and screened as described above. Each compound was tested in duplicate, the data were analyzed by IDBS ActivityBase, and compounds that gave >30% inhibition in both well locations were selected for further study in dose-response.

4.6 IC₅₀ determination of HTS hits

Compounds for the dose-response testing were reordered from BioFocus DPI in 384-well plates, with 20 compounds at 10 mM in 10 μl DMSO in each plate in wells A3-A22. Dose-response compound plates were created by diluting each 10 mM compound solution to 2.5 mM with the addition of 30 μl of DMSO, followed by a 16-point 2-fold serial dilution using 30 μl disposable tips on the Evolution pipetting platform, to a final volume of 20 μl in each well with the highest concentration at 2.5 mM. Compounds from the dose-response compound plate were transferred twice by pintool (2 × 0.11 μl) into 4 μl of H₂O in an assay plate, followed by addition of 5 μl of RmlC, RmlD, and NADPH and 1 μl of TDP-KDX as above for the HTS assay. Each dose-response plate was tested in triplicate using the protocol described above for HTS. The data were analyzed using ActivityBase. Each dose-response assay plate contained compounds in columns 3–22, controls (100% activity) in columns 2 and 24, and blanks (0% activity) in columns 1 and 23. Each compound column (3–22) contained 16 two-fold dilutions of a single compound, ranging in concentration from 55 μM to 1.7 nM. Percent activity was calculated for each concentration of each compound from the change in fluorescence over 90 min, as described above under HTS. IC₅₀ values were calculated from a 4-parameter logistic fit of the change in percent activity with compound concentration using XLfit (IDBS).

Compounds that gave IC₅₀ values of less than 20 μM were tested in buffer alone, in the dose-response assay format, to determine the fluorescence due to the compounds in the absence of enzymes, substrate, and NADPH. One μl of compound from each well of the dose-response compound plate was mixed with 18 μl of H₂O in a V-bottom plate (Greiner 781280), and 4 μl of this dilution mixture was transferred into an assay plate (Corning 3676) containing 6 μl of 83.5 mM MOPS buffer, and the fluorescence at 340/460 nm was monitored over 90 min. The data were analyzed by Excel and dose-response curves were plotted

4.7 Acquisition and synthesis of compounds

The active compound SID 7975595 was obtained three ways: re-supply from the Molecular Libraries Screening Small Molecule Repository, from ChemBridge, and by chemical synthesis (see below). The highly active 77074 was obtained from ChemBridge and chemically synthesized (see below); the remaining compounds shown in Table 2 were prepared by chemical synthesis.

4.8 Chemical synthesis

All solvents and chemicals were purchased from Sigma-Aldrich and Fisher Scientific except that 5-ethyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol was purchased from ChemBridge Corporation, CA, USA; 5-allyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol was purchased from Ryan Scientific, Inc., SC, USA; and 5-allyl-8-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol was purchased from Sigma-Aldrich (rare chemical library). ¹H NMR spectra were recorded at 300 MHz on a Bruker ARX NMR instrument or 500 MHz on a Varian Inova NMR instrument. Accurate mass mass spectrometry in positive mode was performed on an Agilent 6220 TOF mass spectrometer equipped with a MultiMode source selected to be in the dual atmospheric pressure chemical ionization/electrospray ionization mode. Analytical RP-HPLC was conducted on a Shimadzu HPLC system with a Phenomenex C18 column (100Å, 3 μm, 4.6 × 50 mm), flow rate 1.0 mL/min and a gradient of solvent A (water with 0.1% TFA) and solvent B (acetonitrile): 0–2.00 min 100% A; 2.00–8.00 min 0–100% B (linear gradient). UV detection at 218 and 254 nm was used.

4.8.1. Synthesis of triazinoindol-benzimidazolones SID7975595, 77074, and 78531

Alkylation of the corresponding triazino-indol-3-thiols was performed as reported previously ¹⁶^,¹⁷ using optimized reaction conditions (Scheme 1). 5-Allyl-5H-[1,2,4]triazino[5,6-b]indol-3-thiol (0.242 g, 1 mmol), potassium hydroxide (65 mg, 1 mmol, 86.4%), and water (5 mL) were stirred at room temperature for 2h, followed by the addition of 1-(3-chloropropyl)-1,3-dihydro-2H-benzimidazol-2-one (0.234 g, 1 mmol, 90%). The resulting solution was stirred at 90°C for 24h. The reaction mixture was evaporated, and the crude product was purified by Biotage flash column chromatography to yield product 77074 as a light yellow powder.

Scheme 1

1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one, SID7975595, 0.38 g (1 mmol scale), 93.9% yield. ¹H NMR, 300 MHz (CDCl₃): δ9.37 (s, 1H, NH), 8.42 (d, J = 7.6 Hz, 1H), 7.64–7.73 (m, 1H), 7.39–7.49 (m, 2H), 7.00–7.18 (m, 4H), 4.34 (q, J = 7.2 Hz, 2H, NCH₂CH₃), 4.14 (t, J = 6.9 Hz, 2H, NCH₂), 3.46 (t, J = 7.0 Hz, 2H, SCH₂), 2.40 (quintet, J = 7.0 Hz, CH₂), 1.45 (t, J = 7.2 Hz, 3H, CH₃). Mass spectrum m/z (M+Na)⁺ 427.1314 (427.1312 predicted). HPLC purity: >96% (monitored at 218 and 254 nm), t_R = 5.92 min.

1-(3-(5-allyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one, 77074, 0.23 g (1 mmol scale), 55.2% yield. ¹H NMR, 300 MHz (CDCl₃): δ 8.41–8.47 (m, 1H), 8.29 (s, 1H, NH), 7.64–7.71 (m, 1H), 7.43–7.49 (m, 2H), 7.03–7.10 (m, 4H), 5.89–6.03 (m, 1H, CH=(Allyl)), 5.27 (d, J = 10.4 Hz, 1H, =CH^a(Allyl)), 5.18 (d, J = 17.7 Hz, 1H, =CH^b(Allyl)), 4.91 (d, J = 5.3 Hz, 2H, CH₂(Allyl)), 4.12 (t, J = 6.9 Hz, 2H, NCH₂), 3.44 (t, J = 7.0 Hz, 2H, SCH₂), 2.38 (quintet, J = 7.0 Hz, 2H, CH₂). Mass spectrum m/z (M+Na)⁺ 439.1315 (439.1312 predicted). HPLC purity: 100% (monitored at 218 and 254 nm), t_R = 6.02 min.

1-(3-(5-allyl-8-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one, 78531, 40 mg (0.195 mmol scale), 47.6% yield. ¹H NMR, 500 MHz (CDCl₃): δ 8.52 (s, 1H, NH), 8.20 (s, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.31 (d, J = 8.3 Hz, 1H), 7.02–7.08 (m, 4H), 5.89–5.97 (m, 1H, CH=(Allyl)), 5.24 (d, J = 10.5 Hz, 1H, =CH^a(Allyl)), 5.13 (d, J = 17.1 Hz, 1H, =CH^b(Allyl)), 4.85 (d, J = 5.4 Hz, 2H, CH₂(Allyl)), 4.10 (t, J = 6.8 Hz, 2H, NCH₂), 3.41 (t, J = 7.1 Hz, 2H, SCH₂), 2.36 (quintet, J = 7.1 Hz, 2H, CH₂). Mass spectrum m/z (M+Na)⁺ 453.1469 (453.1458 predicted). HPLC purity: 100% (monitored at 218 and 254 nm), t_R = 6.23 min.

4.8.2. Synthesis of triazinoindol-benzimidazolone sulfonation derivatives 78532 and 78533

Sulfonation reaction was carried out according to a reported procedure ¹⁸. Catalytic amounts (ca. 1 mg each) of sodium tungstate dihydrate (Na₂WO₄·2H₂O), methyltrioctylammonium hydrogen sulfate ([CH₃(n-C₈H₁₇)₃N]HSO₄), and phenylphosphonic acid (C₆H₅PO₃H₂) were added to a 25 mL flask, followed by the addition of 150 mg of aqueous 30% H₂O₂. After the mixture was stirred vigorously at room temperature for 10 min, 1-(3-(5-allyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one (77074, 70 mg, 0.168 mmol) was added and stirred at room temperature for 24h. The resulting mixture was evaporated and purified by reverse phase Biotage flash C18 column chromatography to give product 78533 as a light yellow powder.

1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylsulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one, 78532, 15 mg (0.0989 mmol scale), 34.7% yield. ¹H NMR, 500 MHz (CDCl₃): δ 9.34 (s, 1H, NH), 8.57 (d, J = 7.8 Hz, 1H), 7.86 (t, J = 7.8 Hz, 1H), 7.62 (d, J = 8.3 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 6.99–7.10 (m, 4H), 4.53 (q, J = 7.3 Hz, 2H, NCH₂CH₃), 4.14 (t, J = 6.1 Hz, 2H, NCH₂), 3.87 (t, J = 6.8 Hz, 2H, SO₂CH₂), 2.50 (quintet, J = 6.4 Hz, CH₂), 1.52 (t, J = 7.3 Hz, 3H, CH₃). Mass spectrum m/z (M+Na)⁺ 459.1213 (459.1210 predicted). HPLC purity: 100% (monitored at 218 and 254 nm), t_R = 5.60 min.

1-(3-(5-allyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylsulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one, 78533, 40 mg (0.168 mmol scale), 53.1% yield. ¹H NMR, 500 MHz (CDCl₃): δ 9.75 (s, 1H, NH), 8.55 (d, J = 7.6 Hz, 1H), 7.82 (t, J = 7.6 Hz, 1H), 7.54–7.62 (m, 2H), 7.00–7.15 (m, 4H), 5.93–6.02 (m, 1H, CH=(Allyl)), 5.31 (d, J = 10.3 Hz, 1H, =CH^a(Allyl)), 5.23 (d, J = 17.1 Hz, 1H, =CH^b(Allyl)), 5.09 (d, J = 4.2 Hz, 2H, CH₂(Allyl)), 4.15 (br s, 2H, NCH₂), 3.87 (br s, 2H, SO₂CH₂), 2.50 (br s, 2H, CH₂). Mass spectrum m/z (M+Na)⁺ 471.1212 (471.1215 predicted). HPLC purity: 100% (monitored at 218 and 254 nm), t_R = 5.72 min.

4.9 IC₅₀ determination of triazinoindol-benzimidazolones

A slightly different method than that described above was used for determining the IC₅₀ values of triazinoindol-benzimidazolones that were obtained after the screen was complete. Thus the IC₅₀ values of compounds obtained from ChemBridge and by chemical synthesis were determined in 96-well plates by monitoring the conversion of NADPH to NADP via absorbance at 340 nm. The total assay volume was 200 μl of 50 mM 3-(N-morpholino)propanesulfonic acid buffer (MOPS) with 10% glycerol, 0.01% Triton X-100, 1 mM Mg₂Cl₂, at pH 7.4. Test compounds were added in 4 μl of DMSO at a range of concentrations. The remaining components were added to the following concentrations: RmlC (70 nM), RmlD (5 nM), TDP-KDX (200 μM), and NADPH (25 μM). The reaction was started by the addition of RmlC and continuously monitored for 80 min, after which the initial reactions velocities were determined and the IC₅₀ values calculated using the program GraFit (Erithacus Software limited).

4.10 Determination of which Enzyme (RmlC or RmlD) is the Target of Inhibition

The 96-well plate method used to determine IC₅₀ values of triazinoindol-benzimidazolones was performed. Thus, to determine which enzyme is inhibited by SID 7975595, the concentration of one enzyme was varied while maintaining the other constant, and vice versa, and the IC₅₀ of compound SID 7975595 was monitored for changes in IC₅₀ that correlated with changes in enzyme concentration. The RmlC enzyme concentration was held constant at 70 nM while varying RmlD concentration from 5 to 412 nM, and the RmlD concentration was held constant at 5 nM while varying RmlC concentration from 70 to 350 nM, in the presence of 200 μM TDP-KDX and 25 μM NADPH.

4.11 Direct Confirmation of inhibition of RmlC using GC/MS analysis to quantify the product TDP-6-deoxy-L-lyxo-hexopyranosid-4-ulose

An assay to confirm the inhibition of RmlC by SID 7975595 (at the concentrations of 0.25, 0.5, and 5 μM) in the absence of RmlD in which the RmlC product is measured by GC/MS after reduction of the 4-ketogroup and derivatization was performed as previously described ¹¹.

4.12 Determination of the mode of Inhibition by SID 7975595

To determine the mode of inhibition of SID 7975595, the K_m of TDP-KDX was determined in the absence of inhibitor and in the presence of several concentrations of inhibitor. TDP-KDX concentration was varied from 0–100 μM in the presence of SID 7975595 concentrations of 0.1, 0.15, and 0.2 μM. The K_m and V_max were determined by non-linear regression using GraFit. The K_m(obs) was plotted against the concentration of SID 7975595 and the K_i calculated from the slope, which equals K_m/K_i, where K_m is given by the y-axis intercept.

4.13 Determination of time dependence of the onset of inhibition of SID 7975595

Time-dependence of the onset of inhibition by compound SID 7975595 was studied by pre-incubating the compound with RmlC and RmlD enzymes (and NADPH) in 384 well plates for times ranging from 0 to 3 hr before adding TDP-KDX to initiate the enzymatic assay. One μl of compound SID 7975595 from each well of the dose-response compound plate (see above) was mixed with 18 μl per well of H₂O in a 384-well plate (Greiner 781280) and 4 μl of the resulting diluted compound was transferred into a 384-well assay plate (Corning 3676) containing 5 μl of 2x RmlC, RmlD, and NADPH in 83.5 mM MOPS buffer and pre-incubated for 0–3 hr. After pre-incubation, TDP-KDX was added and the enzymes were assayed over 90 min, and IC₅₀ data were analyzed as described above for IC₅₀ determination of HTS hits.

4.14 Determination of the reversibility of SID 7975595 inhibition

The reversibility of inhibition by SID 7975595 was determined using the procedure of Copeland ¹⁹. Thus SID 7975595 at 10 times its IC₅₀ was incubated for 0 and 0.5 hr at 25°C with RmlC at 100 times its final assay concentration in 2 μl buffer, in Eppendorf microcentrifuge tubes. After incubation, the compound-RmlC mixture was diluted 100-fold to a final volume of 200 μl, RmlD, TDP-KDX, and NADPH were added, and the activity of the enzyme was measured by transferring 10 μl of the assay mixture into a 384-well assay plate and monitoring the decrease in NADPH fluorescence over 200 min as described above. Control assays were set-up in the absence of compound.

4.15 Modeling the binding of triazinoindol-benzimidazolones in the active site of RmlC

Docking of SID 7975595 and its analogs was performed using both Glide ²⁰ and Autodock Vina ¹³. As a control experiment, TDP-Rha was re-docked into RmlC using both programs. The RmlC dimer structure was taken from pdb entry 2ixc (5). Protonation states of protein residues were initially assigned based on pKa calculations using PROPKA ²¹^,²². Key residues at the active site were then inspected visually to make sure that their protonation states were consistent with experimental findings. In particular, Lys72 was given a +1 charge despite of a predicted pKa of ~7, and His62, His119 were kept neutral with protons on their ε-nitrogen. The protein was then prepared using the Schrodinger Protein Preparation Wizard ²³^–²⁵ and AutodockTools ²⁶ for Glide and Autodock Vina docking, respectively. Initial structures of SID 7975595 and its analogs listed in Table 1 were prepared using Ligprep ²⁷ or DiscoveryStudio ²⁸. Docking with Glide was performed using both the standard precision (SP) and the extra precision (XP) modes, with the ligand van der Waals radii scaled by 0.8. Docking with Autodock Vina was performed with an exhaustiveness factor of 8.

4.16 MIC Determination

The MIC of SID 7975595 and structural analogs against Mycobacterium tuberculosis (H37Rv) was determined by the microbroth dilution method as described by Sun et al ²⁹.

4.17 Cytotoxicity Studies with Human Aortic Endothelial (HAE) Cells

Cytotoxicity of compound SID 7975595 in mammalian cells was tested in HEA cells by seeding 1000 cells/25 μl/well in white 384-well tissue culture treated plates and incubating at 37 °C for 24 hr before treating with compound and incubating for an additional 24 hr at 37 °C and measuring luminescence. To prepare SID 7975595, 3μl of 10 mM SID 7975595 in DMSO was mixed with 47 μl of EGM-2 endothelial cell media and 25 μl of this mixture was transferred into 25 μl of media for a 16-point, 2-fold serial dilution ranging in concentration from 600 μM to 18 nM. As controls, 6 μl of doxorubicin (positive control) and DMSO (solvent control) were mixed with 94 μl of media and 25 μl of each was transferred into 25 μl media for a 16 point, two-fold serial dilution, where the doxorubicin concentrations were the same as the SID 7975595 concentrations (600 μM to 18 nM) and the DMSO only concentration was the same as the DMSO concentration in both the SID 7975595 and doxorubicin tests. Five μl of each of the serial dilutions were added to cells in 25 μl media for final compound concentrations of 100 μM to 3 nM. Luminescence was measured on the Envision microplate reader after the addition of 30 μl of CellTiter-Glo and incubation for 10 min. Each plate was tested in triplicate.

Acknowledgments

We gratefully acknowledge the support of NIH grant P01 AI 057846 (MRM, REL); NIH grant U54-HG003915 (SLD); and grants from NSF, NIH, HHMI, CTBP and NBCR (JAM). We also thank Jim Naismith for helpful discussions and for providing the E. coli strain over expressing RmlB from Salmonella typhimurium. We thank Huiyan Jing for assistance with the cytotoxicity assay.

Footnotes

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Reference List

1. O’Brien RJ, Nunn PP. Am J Respir Crit Care Med. 2001;163:1055–1058. [PubMed]

2. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Lancet. 2006;368:1575–1580. [PubMed]

3. Van Rie A, Enarson D. Lancet. 2006;368:1554–1556. [PubMed]

4. Barry CE, Crick DC, McNeil MR. Infect Disorders-Drug Targets. 2007;7:182–202. [PubMed]

5. Li W, Xin Y, McNeil MR, Ma Y. Biochem Biophys Res Commun. 2006;342:170–178. [PubMed]

6. Ma Y, Pan F, McNeil MR. J Bacteriol. 2002;184:3392–3395. [PMC free article] [PubMed]

7. Dong C, Major LL, Srikannathasan V, Errey JC, Giraud MF, Lam JS, Graninger M, Messner P, McNeil MR, Field RA, Whitfield C, Naismith JH. J Mol Biol. 2007;365:146–159. [PMC free article] [PubMed]

8. Blankenfeldt W, Kerr ID, Giraud MF, McMiken HJ, Leonard G, Whitfield C, Messner P, Graninger M, Naismith JH. Structure (Camb) 2002;10:773–786. [PubMed]

9. Ma Y, Stern RJ, Scherman MS, Vissa V, Yan W, Jones VC, Zhang F, Franzblau SG, Lewis WH, McNeil MR. Antimicrob Agents Chemother. 2001;45:1407–1416. [PMC free article] [PubMed]

10. Zhang JH, Chung TDY, Oldenburg KR. Journal of Biomolecular Screening. 1999;4:67–73. [PubMed]

11. Stern RJ, Lee TY, Lee TJ, Yan W, Scherman MS, Vissa VD, Kim SK, Wanner BL, McNeil MR. Microbiology. 1999;145:663–671. [PubMed]

12. Cheng Y, Prusoff WH. Biochemical Pharmacology. 1973;22:3099–3108. [PubMed]

13. Trott O, Olson AJ. J Comput Chem. 2009 On line ahead of print.

14. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Journal of Medicinal Chemistry. 2006;49:6177–6196. [PubMed]

15. Allard STM, Giraud MF, Whitfield C, Messner P, Naismith JH. Acta Crystallogr D Biol Crystallogr. 2000;56(Pt 2):222–225. [PubMed]

16. Hamid HA, Mousaad A, Ramadan ES, Ashry ESHE. Heterocyclic Communications. 1999;5:473–480.

17. Kgokong JL, Smith PP, Matsabisa GM. Bioorganic & Medicinal Chemistry. 2005;13:2935–2942. [PubMed]

18. Sato K, Hyodo M, Aoki M, Zheng XQ, Noyori R. Tetrahedron. 2001;57:2469–2476.

19. Copeland RA. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. J. Wiley; Hoboken, N.J: 2005.

20. Glide, version 5.5. Schrodinger LLC; New York: 2009.

21. Li H, Robertson AD, Jensen JH. Proteins-Structure Function and Bioinformatics. 2005;61:704–721. [PubMed]

22. Bas DC, Rogers DM, Jensen JH. Proteins-Structure Function and Bioinformatics. 2008;73:765–783. [PubMed]

23. Prime version 2.1. Schrodinger, LLC; New York, NY: 2009.

24. Impact version 5.5. Schrodinger, LLC; New York, NY: 2009.

25. Epik version 2.0. Schrodinger, LLC; New York, NY: 2009. Schroding Suite 2009 Protein Preparation Wizard.

26. Sanner MF. Journal of Molecular Graphics & Modelling. 1999;17:57–61. [PubMed]

27. LigPrep, version 2.3. Schrodinger, LLC; New York, NY: 2009.

28. DiscoveryStudio, version 2.1. Accelrys Software Inc; 2009.

29. Sun D, Scherman MS, Jones V, Hurdle JG, Woolhiser LK, Knudson SE, Lenaerts AJ, Slayden RA, McNeil MR, Lee RE. Bioorganic & Medicinal Chemistry. 2009;17:3588–3594. [PMC free article] [PubMed]